One example of this is GSK’s commitment to make its new malaria vaccine RTS,S affordable, the company planning to price it at £8.50 (10.42 US dollars) per child, based on demand of around 100 ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Russia has launched a widespread disinformation campaign in Africa attacking the new game-changing British-made malaria ...

Cameroon has begun using Mosquirix, the first of two recently approved malaria vaccines. The vaccine, sold by GlaxoSmithKline, is about 39% effective and requires four doses, according to NPR.

Several observations point toward the possibility of a vaccine development strategy against the disease-associated blood stage form of the malaria parasite. Protection against clinical malaria ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year, citing lower-than-expected demand. The company said it’s now expecting a low single-digit fall in vaccine sales this ...

EMVI = European malaria vaccine initiative; GLURP = Glutamate-rich protein; GSK = GlaxoSmithKline; LSA = Liver-stage antigen; LSP = Long-synthetic peptide; ME-TRAP = Multiepitope-thrombospondin ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work ...